Mesoblast vs Vericel
MESO and VCEL side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How MESO and VCEL compare
Mesoblast grew revenue faster over the last twelve months (599% versus 25.3% for Vericel).
Vericel keeps more of each dollar of sales as profit, with a net margin of 10.3% compared with −47.8% at Mesoblast.
Vericel scores higher on the StockData Score (16 against 6 for Mesoblast), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | MESO | VCEL |
|---|---|---|
| Size and price | ||
| Market cap | – | $3.0B |
| Share price | $13.65 | $59.45 |
| Change, 1 year | −10.3% | 52.5% |
| Change, 5 years | 9.4% | 34.1% |
| Beta (5Y) | 1.51 | 1.04 |
| Employees | 108 | 398 |
| StockData Score | ||
| Total score | 6 | 16 (better) |
| Valuation score | 0 | 0 |
| Growth score | 3 | 5 (better) |
| Performance score | 2 | 5 (better) |
| Health score | 1 | 6 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | – | 101× |
| P/S | – | 9.4× |
| P/B | – | 7.9× |
| EV/EBITDA | – | 70.8× |
| P/FCF | – | 52.6× |
| FCF yield | – | 1.9% |
| Fair value | – | $16.78 |
| Margin of safety | – | −254% |
| Growth | ||
| Revenue growth (TTM) | 599% (better) | 25.3% |
| Revenue growth, 5Y average | 74.5% (better) | 17.3% |
| Net income growth (TTM) | – | 155% |
| EPS growth (TTM) | – | 211% |
| EPS growth, 5Y average | – | 39.8% |
| Profitability | ||
| Gross margin | 86.1% (better) | 74.5% |
| Operating margin | – | 8.3% |
| Net margin | −47.8% | 10.3% (better) |
| FCF margin | −37.1% | 17.9% (better) |
| Return on equity | – | 9.4% |
| Return on invested capital | – | 10.6% |
| Financial health | ||
| Debt / equity | – | 0.00 |
| Interest coverage | – | 42.0× |
| Current ratio | 2.43 | 5.13 (better) |
| Altman Z-score | – | 14.07 |
| Piotroski F-score | 5 | 7 (better) |
| Dividends and buybacks | ||
| Buyback yield | – | −0.25% |
| Shareholder yield | – | −0.25% |
| Ownership | ||
| Held by institutions | 0.30% | 108% |
| Held by insiders | 37.3% | 1.3% |
| Insider net buying, 12 months | $37.5M (better) | −$11.0M |
| Short interest, % of float | – | 10.6% |
Go deeper
- MESO stock overview
- MESO income statement
- MESO valuation and score
- VCEL stock overview
- VCEL income statement
- VCEL valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.